Resistance-Associated Gene Variants Found In Hep C Patients Who Received First

Resistance-Associated Gene Variants Found In Hep C Patients Who Received First
First-generation triple therapies for hepatitis C virus (HCV) infection are being phased out in favor of next-generation interferon-free direct-acting antiviral agents (DAAs). When the old drugs are no longer available—the protease inhibitor …
Read more here.

Public Health encourages hepatitis awareness
Hepatitis A and B are vaccine-preventable diseases, whereas hepatitis C has no vaccine. The U.S. Food and Drug Administration has approved new medications for the treatment of chronic hepatitis C virus infection, which can now cure the disease …
Read more here.

Incidence of HCV May Be Underestimated
Less than 1% of a group of acute HCV patients participating in a long-term study of the disease had been reported to the Centers for Disease Control and Prevention (CDC), largely because data that would have triggered reporting were either not readily …
Read more here.

AASLD Updates HCV Guidelines
An update to the 2014 guidelines for management of hepatitis C virus (HCV) infection has been issued by the American Association for the Study of Liver Diseases (AASLD), in partnership with the Infectious Diseases Society of America (IDSA) and the …
Read more here.

GUEST COLUMN: Various kinds of hepatitis
Some people who have hepatitis have no symptoms. Others may have loss of appetite, fatigue, nausea, … Hepatitis C virus (HCV) usually causes a chronic condition that can lead to cirrhosis of the liver and liver cancer. Hepatitis C virus is mostly …
Read more here.

Cure Hep C and You May See Your Liver Health Improve
One year after treatment, the probability of seeing FibroScan liver stiffness tests values drop by 30 percent was 51 percent among those cured of hep C and 21 percent among those who were not cured. Two years after treatment, the respective rates of …
Read more here.

FDA extends use of Promacta in young children with rare blood disorder
The safety and efficacy of Promacta in pediatric patients younger than one year with ITP, or in pediatric patients with thrombocytopenia associated with chronic hepatitis C and severe aplastic anemia, have not been established. The FDA granted Promacta …
Read more here.

Advocates Decry Harvoni Denied Insurance as Shortsighted
Harvoni is a relatively new treatment developed and marketed by Gilead Science and AbbVie that has been found to be 90 percent effective in treating hepatitis C. A companion hepatitis C treatment marketed by the same duo, Sovaldi, approaches Harvoni in …
Read more here.


Leave a Reply